Drugs / VESIGENURTUCEL-L
VESIGENURTUCEL-L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02010203 | Dec 2013 → Dec 2017 | urinary bladder cancer | Heat Biologics | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VESIGENURTUCEL-L | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301571 ↗ |
| Known as | HS-410 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02010203 ↗ |
| Known as | UM-UC-3-gp96-Ig-HLA-A1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301571 ↗ |
| Modality | Vaccine | “Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96” NCT02010203 ↗ |